Search - tctmd.com

Displaying 401 - 420 of 830

Sort: Relevancy | Date

News Daily News

Coronary Calcium-Guided Statin Strategy Cost-effective in African-Americans

Michael O'Riordan

May 15, 2020

News Daily News

FOURIER Surveys Reassure About Cognitive Safety of Evolocumab

Todd Neale

May 06, 2020

News Daily News

Alirocumab ‘Modestly’ Cost-effective at Lower List Price: ODYSSEY OUTCOMES

Michael O'Riordan

May 04, 2020

News Daily News

Different Markers of Dyslipidemia Could Help Fine-tune CVD Prevention

Yael L. Maxwell

April 28, 2020

News Features

COVID-19 Lockdown Inactivity May Spell Trouble for CVD Prevention

Michael O'Riordan

April 24, 2020

News Features

Obesity and COVID-19: Theories and Blame Fill the Scientific Void

Shelley Wood

April 21, 2020

News Daily News

Adherence to Healthy Habits Linked to Years Free of Chronic Disease

Michael O'Riordan

April 08, 2020

News Conference News ACC 2020

Alirocumab Successfully Reduces LDL Cholesterol in Homozygous FH: ODYSSEY HoFH

Yael L. Maxwell

April 06, 2020

News Conference News ACC 2020

Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT

Todd Neale

April 02, 2020

News Conference News ACC 2020

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

Michael O'Riordan

April 02, 2020

Hope for these hard-to-treat patients: more than half saw ≥ 50% decrease at 24 weeks, regardless of LDL receptor function.

News Conference News ACC 2020

Evinacumab Cuts LDL Cholesterol in Homozygous FH

Yael L. Maxwell

April 01, 2020

Presentation ACC 2020

Evinacumab in Patients with Homozygous Familial Hypercholesterolemia

Presenter: Frederick Raal

March 30, 2020

Presentation ACC 2020

EPA Levels and Cardiovascular Outcomes in the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial

Presenter: Deepak L. Bhatt

March 30, 2020

Presentation ACC 2020

Alirocumab Efficacy And Safety In Adults With Homozygous Familial Hypercholesterolemia (ODYSSEY HoFH)

Presenter: Dirk J. Blom

March 30, 2020

News Daily News

Inclisiran Data in NEJM Prompt Talk of What Comes Next

Caitlin E. Cox

March 24, 2020

News Daily News

Ideal CV Health Over the Long Term Linked With Better Survival, Less Disease

Michael O'Riordan

March 13, 2020

News Daily News

Olive Oil Consumption Linked to CVD Benefits in the US

Shelley Wood

March 09, 2020

News Daily News

One Egg a Day? No Link to Risk of CVD, Mega-Meta-analysis Says

Michael O'Riordan

March 06, 2020

News Daily News

FDA Approves New Lipid-Lowering Drug, Bempedoic Acid

Shelley Wood

February 26, 2020

News Daily News

Long-term Evolocumab Safe, Effective for Familial Hypercholesterolemia Treatment

Yael L. Maxwell

February 12, 2020

Advertisement

Coronary Calcium-Guided Statin Strategy Cost-effective in African-Americans

FOURIER Surveys Reassure About Cognitive Safety of Evolocumab

Alirocumab ‘Modestly’ Cost-effective at Lower List Price: ODYSSEY OUTCOMES

Different Markers of Dyslipidemia Could Help Fine-tune CVD Prevention

COVID-19 Lockdown Inactivity May Spell Trouble for CVD Prevention

Obesity and COVID-19: Theories and Blame Fill the Scientific Void

Adherence to Healthy Habits Linked to Years Free of Chronic Disease

Alirocumab Successfully Reduces LDL Cholesterol in Homozygous FH: ODYSSEY HoFH

Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

Evinacumab Cuts LDL Cholesterol in Homozygous FH

Evinacumab in Patients with Homozygous Familial Hypercholesterolemia

EPA Levels and Cardiovascular Outcomes in the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial

Alirocumab Efficacy And Safety In Adults With Homozygous Familial Hypercholesterolemia (ODYSSEY HoFH)

Inclisiran Data in NEJM Prompt Talk of What Comes Next

Ideal CV Health Over the Long Term Linked With Better Survival, Less Disease

Olive Oil Consumption Linked to CVD Benefits in the US

One Egg a Day? No Link to Risk of CVD, Mega-Meta-analysis Says

FDA Approves New Lipid-Lowering Drug, Bempedoic Acid

Long-term Evolocumab Safe, Effective for Familial Hypercholesterolemia Treatment

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content